Steve Pascolo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8592058/publications.pdf

Version: 2024-02-01

44 papers	3,151 citations	230014 27 h-index	340414 39 g-index
45 all docs	45 docs citations	45 times ranked	4023 citing authors

#	Article	IF	Citations
1	Epitranscriptomics modifier pentostatin indirectly triggers Toll-like receptor 3 and can enhance immune infiltration in tumors. Molecular Therapy, 2022, 30, 1163-1170.	3.7	2
2	Increased Chlormethine-Induced DNA Double-Stranded Breaks in Malignant T Cells from Mycosis Fungoides Skin Lesions. JID Innovations, 2022, 2, 100069.	1.2	10
3	Synthetic Messenger RNA-Based Vaccines: From Scorn to Hype. Viruses, 2021, 13, 270.	1.5	53
4	Lipofection with Synthetic mRNA as a Simple Method for T-Cell Immunomonitoring. Viruses, 2021, 13, 1232.	1.5	0
5	Protamine-Based Strategies for RNA Transfection. Pharmaceutics, 2021, 13, 877.	2.0	42
6	Implications of mRNA-based SARS-CoV-2 vaccination for cancer patients. , 2021, 9, e002932.		7
7	mRNA-Based Anti-TCR CDR3 Tumour Vaccine for T-Cell Lymphoma. Pharmaceutics, 2021, 13, 1040.	2.0	7
8	Enhancement of antibody-dependent cellular cytotoxicity is associated with treatment response to extracorporeal photopheresis in SÃ©zary syndrome. OncoImmunology, 2021, 10, 1873530.	2.1	6
9	Vaccines against COVID-19: Priority to mRNA-Based Formulations. Cells, 2021, 10, 2716.	1.8	17
10	Functional differences between protamine preparations for the transfection of mRNA. Drug Delivery, 2020, 27, 1231-1235.	2.5	26
11	Blockade of programmed cell death protein 1 (PD-1) in SÃ©zary syndrome reduces Th2 phenotype of non-tumoral T lymphocytes but may enhance tumor proliferation. OncoImmunology, 2020, 9, 1738797.	2.1	32
12	Sensitivity and specificity of T-cell receptor PCR BIOMED-2 clonality analysis for the diagnosis of cutaneous T-cell lymphoma. European Journal of Dermatology, 2020, 30, 12-15.	0.3	7
13	Design of in vitro Transcribed mRNA Vectors for Research and Therapy. Chimia, 2019, 73, 391.	0.3	28
14	Charting DENR-dependent translation reinitiation uncovers predictive uORF features and links to circadian timekeeping via Clock. Nucleic Acids Research, 2019, 47, 5193-5209.	6.5	30
15	Divergent LAG-3 versus BTLA, TIGIT, and FCRL3 expression in SÃ©zary syndrome. Leukemia and Lymphoma, 2019, 60, 1899-1907.	0.6	23
16	Generation of Immunostimulating 130 nm Protamineâ€“RNA nanoparticles. Methods in Molecular Biology, 2017, 1499, 155-163.	0.4	12
17	Phase I study of a chloroquineâ€“gemcitabine combination in patients with metastatic or unresectable pancreatic cancer. Cancer Chemotherapy and Pharmacology, 2017, 80, 1005-1012.	1.1	61
18	Time to use a dose of Chloroquine as an adjuvant to anti-cancer chemotherapies. European Journal of Pharmacology, 2016, 771, 139-144.	1.7	98

#	Article	IF	Citations
19	Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy. OncoImmunology, 2016, 5, e1108511.	2.1	41
20	Immunity to Pathogens Taught by Specialized Human Dendritic Cell Subsets. Frontiers in Immunology, 2015, 6, 527.	2.2	47
21	The messenger's great message for vaccination. Expert Review of Vaccines, 2015, 14, 153-156.	2.0	28
22	CD141+ dendritic cells produce prominent amounts of IFN-Î± after dsRNA recognition and can be targeted via DEC-205 in humanized mice. Blood, 2013, 121, 5034-5044.	0.6	113
23	Enhancement of Gene Gun-Induced Vaccine-Specific Cytotoxic T-Cell Response by Administration of Chemotherapeutic Drugs. Methods in Molecular Biology, 2013, 940, 189-198.	0.4	0
24	Promiscuous survivin peptide induces robust CD4⁺ Tâ€cell responses in the majority of vaccinated cancer patients. International Journal of Cancer, 2012, 131, 140-149.	2.3	70
25	The form of NY-ESO-1 antigen has an impact on the clinical efficacy of anti-tumor vaccination. Vaccine, 2011, 29, 3832-3836.	1.7	16
26	Gemcitabine depletes regulatory Tâ€cells in human and mice and enhances triggering of vaccineâ€specific cytotoxic Tâ€cells. International Journal of Cancer, 2011, 129, 832-838.	2.3	69
27	Intradermal Vaccinations With RNA Coding for TAA Generate CD8+ and CD4+ Immune Responses and Induce Clinical Benefit in Vaccinated Patients. Molecular Therapy, 2011, 19, 990-999.	3.7	199
28	Particle size and activation threshold: a new dimension of danger signaling. Blood, 2010, 115, 4533-4541.	0.6	103
29	Modified tumour antigen-encoding mRNA facilitates the analysis of naturally occurring and vaccine-induced CD4 and CD8 T cells in cancer patients. Cancer Immunology, Immunotherapy, 2009, 58, 325-338.	2.0	27
30	Novel multiâ€peptide vaccination in Hlaâ€A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate, 2009, 69, 917-927.	1.2	97
31	Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma Patients. Journal of Immunotherapy, 2009, 32, 498-507.	1.2	301
32	Plasmid DNA- and messenger RNA-based anti-cancer vaccination. Immunology Letters, 2008, 115, 33-42.	1.1	81
33	Vaccination with Messenger RNA (mRNA). Handbook of Experimental Pharmacology, 2008, , 221-235.	0.9	107
34	Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNA. Journal of Immunotherapy, 2008, 31, 180-188.	1.2	216
35	Characterization of the ribonuclease activity on the skin surface. Genetic Vaccines and Therapy, 2006, 4, 4.	1.5	68
36	Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. European Journal of Immunology, 2006, 36, 2807-2816.	1.6	101

#	Article	IF	Citations
37	Vaccination With Messenger RNA. , 2006, 127, 23-40.		44
38	HLA class I transgenic mice: development, utilisation and improvement. Expert Opinion on Biological Therapy, 2005, 5, 919-938.	1.4	38
39	Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA. European Journal of Immunology, 2005, 35, 1557-1566.	1.6	183
40	Production and characterization of amplified tumor-derived cRNA libraries to be used as vaccines against metastatic melanomas. Genetic Vaccines and Therapy, 2005, 3, 6.	1.5	29
41	Immunostimulating capacities of stabilized RNA molecules. European Journal of Immunology, 2004, 34, 537-547.	1.6	128
42	Messenger RNA-based vaccines. Expert Opinion on Biological Therapy, 2004, 4, 1285-1294.	1.4	127
43	HLA-A2.1â€“restricted Education and Cytolytic Activity of CD8+ T Lymphocytes from Î²2 Microglobulin (Î²2m) HLA-A2.1 Monochain Transgenic H-2Db Î²2m Double Knockout Mice. Journal of Experimental Medicine, 1997, 185, 2043-2051.	4.2	457
44	Plasmid DNA and Messenger RNA for Therapy. , 0, , 971-1011.		0